This systematic review and meta-analysis show that the risk of biopsy-proven acute rejection, patients mortality, graft loss, and infection-related outcomes do not differ between kidney transplant patients who use PPIs versus those who take H2RAs as acid suppressant agents. The higher rates of antibody mediated rejection and hypomagnesemia, and lower level of kidney function at one year after transplantation were seen in the PPIs group.

This study compared the cardiovascular adverse outcomes in patients with breast cancer receiving tamoxifen & aromatase inhibitors. The study reports an insignificant increase in the events of stroke, angina, myocardial infarction & heart failure in breast cancer patients treated with aromatase inhibitors as compared to tamoxifen.

An electronic questionnaire was distributed to all 40 heart and lung transplant centres in Brazil to explore clinical pharmacy activities and compared them with accredited programs in the United States. From 22 centres respondents, ten (45.5%) declared not to have a pharmacist at any part of the transplantation process, which translated into 158 (37.6%) transplant recipients without any direct pharmaceutical care. When compared to U.S. centres, there was a significantly lower insertion of clinical pharmacist activities among Brazilian centres.

Betalactam antibiotic desensitization may be a key therapeutic option for treating multidrug-resistant infections in patients with confirmed allergy and in those strongly suspected to have Type I hypersensitivity. Detailed information about compounding, dilution and stability is crucial to ensure safe and successful desensitization processes.

The IMMENSE study is a randomized controlled trial investigating the impact of a multi-step pharmacist-led interdisciplinary intervention on emergency medical visits. We found that 54.8% of patients received all intervention steps if appropriate. Many discrepancies and medication-related problems were identified and solved for the patients and may explain a potential effect of the IMMENSE study.

Our study was of potential clinical significance to provide the real-world evidence that osimertinib plus anlotinib demonstrated encouraging clinical outcomes and acceptable safety for patients with previously treated EGFR T790M-positive NSCLC preliminarily.

The ACCP, ESC/ESA and ACC/AHA CPGs were recommended. There is a need for high-quality prospective studies assessing different management strategies on this issue. Given the lack of consensus, the results of this study will help to guide perioperative dual antiplatelet management strategies for patients with coronary stents who are undergoing noncardiac surgery.

BMI is one of the critical factors affecting the pharmacodynamic index of propofol target-controlled infusion, and the induction time decreased progressively with increasing BMI. The Schnider model might underpredict doses of propofol for underweight individuals.

Drug-drug interactions investigated in patients prescribed apixaban with amiodarone or diltiazem with statins (atorvastatin, rosuvastatin, and simvastatin).

An impaired liver function is a risk factor for drug safety. The MELD score can be used as a screening tool for hepatic impairment when appropriately considering correct parameter adjustment for calculation and renal insufficiency and INR-elevating drugs as interfering factors.

Many premature infants will experience apnoea of prematurity (AOP). Because the treatment options are so limited, we explore the epidemiology of AOP, with the ultimate hope of learning how to decrease its incidence. Until then, better pharmacotherapeutic options are needed.

Esomeprazole when administered via a syringe driver over 24 hours appears well tolerated and effective for the prophylaxis of gastrointestinal bleeding, prevention of re-bleeding, and for the symptomatic management of both dyspepsia, and reflux. Overall, this series adds to the limited evidence base for using subcutaneous proton pump inhibitors in the palliative demographic.

CMV viral load by date and medications. The black line represents the CMV viral load measured in IU/ml over time. The orange arrows indicate the timing and results of resistance testing. The blue block shows the antiviral treatment for CMV the patient was receiving on the corresponding dates. The green blocks demonstrate the patient's treatment for GVHD with non-steroidal T cell–depleting immunosuppressants (ruxolitinib, infliximab, basiliximab), and the pink blocks indicate the steroid dose our patient received for GVHD. Our patient's CMV PCR decreased dramatically upon initiation of maribavir and letermovir. Abbreviations: MP, methylprednisolone; VGCV, valganciclovir; GCV, ganciclovir; FOS, foscarnet; LTV, letermovir; LEF, leflunomide; MBV, maribavir.

Pravastatin concentrations in the maternal serum, cord blood, infant serum and breast milk of two nursing mothers with APS and evaluated the safety of their infants. The infants delivered from the mothers who were treated with pravastatin during pregnancy had no apparent adverse effects.